Pre-medication with oral anticoagulants is associated with better outcomes in a large multinational COVID-19 cohort with cardiovascular comorbidities
ConclusionsPre-existing OAC is protective in COVID-19, irrespective of anticoagulation regime during hospital stay and independent of the stage and course of disease.Graphic abstract
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
More News: Bleeding | Cardiology | Cardiovascular | Coronavirus | COVID-19 | Heart | SARS | Study | Thrombosis